BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
KEYTRUDA (pembrolizumab) by Merck & Co. is programmed death receptor-1-directed antibody interactions [moa]. Approved for melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma and 2 more indications. First approved in 2014.
KEYTRUDA (pembrolizumab) is a monoclonal antibody that blocks the Programmed Death Receptor-1 (PD-1), a checkpoint inhibitor that enhances anti-tumor immune response. Approved by the FDA on September 4, 2014, it is administered intravenously as a solution and represents a foundational immunotherapy across multiple cancer indications. The drug works by releasing the brakes on T-cell mediated immunity, allowing the immune system to recognize and attack cancer cells more effectively. KEYTRUDA is positioned as a standard-of-care first-line and combination therapy across melanoma, non-small cell lung cancer, head and neck cancers, and other solid tumors.
$0.1BPart D
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications (5)
Worked on KEYTRUDA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.